Clinical Trial

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

Study acronym: SORENTO
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with intensified treatment with CAM2029.
Trial Details
NCT Number NCT05050942
Lead Sponsor Camurus AB
Conditions Gastro-enteropancreatic Neuroendocrine Tumor
Enrollment 332 participants
Start Date 2021-10-22
Primary Completion 2026-07 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-06-11